Brokerage firm Jefferies Maintains its rating on Celldex Therapeutics(NASDAQ:CLDX). In a research note issued to the investors, the brokerage major Raises the price-target to $5.00 per share. The shares have been rated Hold. The rating by Jefferies was issued on Aug 9, 2016.
Celldex Therapeutics (CLDX) shares turned negative on Wednesdays trading session with the shares closing down -0.15 points or -3.39% at a volume of 13,08,056. The pessimistic mood was evident in the company shares which never went considerably beyond the level of $4.42. The peak price level was also seen at $4.42 while the days lowest was $4.27. Finally the shares closed at $4.27. The 52-week high of the shares is $18.62 while the 52-week low is $2.96. According to the latest information available, the market cap of the company is $429 M.
Celldex Therapeutics(CLDX) last announced its earnings results on Aug 8, 2016 for Fiscal Year 2016 and Q2.Company reported revenue of $1.39M. Analysts had an estimated revenue of $850.00K. Earnings per share were $-0.32. Analysts had estimated an EPS of $-0.34.
Several Insider Transactions has been reported to the SEC. On Nov 25, 2015, Avery W Catlin (Sr. VP & CFO) sold 25,000 shares at $18.00 per share price.Also, On Aug 26, 2015, Larry Ellberger (director) purchased 5,000 shares at $14.00 per share price.On Aug 14, 2015, Anthony S Marucci (CEO) purchased 5,800 shares at $16.81 per share price, according to the Form-4 filing with the securities and exchange commission.
Celldex Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of several immunotherapy technologies for the treatment of cancer and other difficult-to-treat diseases. The Company is engaged in the development of targeted immunotherapeutics comprised of antibodies adjuvants and monotherapies and antibody-drug conjugates that treat cancers and other diseases. Its lead drug candidates include rindopepimut also referred to as Rintega and CDX-110 and glembatumumab vedotin also referred to as CDX-011. Its early-stage drug candidates in clinical development includes varlilumab also referred to as CDX-1127 a fully human therapeutic monoclonal antibody for cancer indications CDX-1401 a targeted immunotherapeutic for cancer indications and CDX-301 an immune cell mobilizing agent and dendritic cell growth factor. CDX-014 is a preclinical product under development for the treatment of cancer.